Paper Details

  1. Home
  2. Paper Details

AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.

Author: OlneyNicholas, RosenHoward

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study reviewed AVANIR Pharmaceuticals Inc's development of AVP-923 (Zenvia, Neurodex) for the treatment of pseudobulbar affect (PBA) and neuropathic pain associated with diabetic peripheral neuropathy. The drug consists of a combination of dextromethorphan hydrobromide (DM) and quinidine sulfate (Q). Initial clinical data for AVP-923 in the treatment of PBA demonstrated the combination was effective, but exhibited significant side effects.
Paper Details　
Original Abstract of the Article :
AVANIR Pharmaceuticals Inc, under license from Irisys Research & Development, is developing AVP-923 (Zenvia, Neurodex) for the treatment of pseudobulbar affect (PBA; in collaboration with Medison Pharma Ltd) and neuropathic pain associated with diabetic peripheral neuropathy. PBA, the main indicatio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20373255

データ提供：米国国立医学図書館（NLM）

A Novel Approach to Treating Pseudobulbar Affect: The Promise of AVP-923

The field of [neurology] is constantly seeking new treatments for [pseudobulbar affect (PBA)], a debilitating neurological disorder. This study explores the potential of [AVP-923 (Zenvia, Neurodex)] as a treatment option for PBA and [neuropathic pain]. The researchers discuss the development of [AVP-923], a combination of [dextromethorphan hydrobromide and quinidine sulfate], and its potential to address these conditions.

AVP-923: A New Hope for PBA Treatment

The researchers highlight the potential of [AVP-923] as a promising treatment option for [PBA]. They emphasize the need for further research to optimize the dosage and address safety concerns. This research provides a hopeful glimpse into the potential for new treatments to address the challenges of [PBA].

Living with PBA and Neuropathic Pain

This study underscores the ongoing search for effective treatments for [PBA and neuropathic pain]. It highlights the potential of [AVP-923] as a promising candidate for treatment but emphasizes the need for further research and careful consideration of potential side effects. It is important to consult with a healthcare professional for individualized treatment plans and ongoing management of these conditions.

Dr.Camel's Conclusion

Think of the desert as a place where unexpected challenges can arise. Pseudobulbar affect, like a sudden sandstorm, can disrupt daily life. This research offers a potential solution, AVP-923, a combination of treatments that could help individuals navigate this challenging condition.

Date :
  1. Date Completed 2010-09-14
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20373255

DOI: Digital Object Identifier

20373255

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.